Nanoparticle-programmed immune cells can slow progression of leukemia in mouse model
Can't see this email? View it online
   
  April 18, 2017  
  Nanomedicine  
  The latest nanomedicine news from News Medical  
 Nanoparticle-programmed immune cells can slow progression of leukemia in mouse modelNanoparticle-programmed immune cells can slow progression of leukemia in mouse model
 
Researchers at Fred Hutchinson Cancer Research Center have developed biodegradable nanoparticles that can be used to genetically program immune cells to recognize and destroy cancer cells -- while the immune cells are still inside the body.
 
 
 Novel non-invasive technique can deliver drugs to the brain via nanoparticlesNovel non-invasive technique can deliver drugs to the brain via nanoparticles
 
Delivering life-saving drugs directly to the brain in a safe and effective way is a challenge for medical providers.
 
   Researchers discover potential novel strategy for improving immunotherapy against cancerResearchers discover potential novel strategy for improving immunotherapy against cancer
 
Researchers at the University of North Carolina Lineberger Comprehensive Cancer Center have discovered a potential novel strategy for improving drugs that unleash the immune system against cancer -- by binding two compounds to a nanoparticle.
 
   Scientists develop lab-scale laser device for treatments based on optical hyperthermia applicationsScientists develop lab-scale laser device for treatments based on optical hyperthermia applications
 
Researchers from Universidad Politécnica de Madrid, in collaboration with Universitat Politécnica de Valencia and CIBER's Bioengineering, Biomaterials and Nanomedicine, have designed a laser device specifically designed for optical hyperthermia applications.
 
   Hebrew University announces launch of new Center for conducting research on cannabinoidsHebrew University announces launch of new Center for conducting research on cannabinoids
 
The Hebrew University of Jerusalem has announced the launch of a Multidisciplinary Center on Cannabinoid Research.
 
 Horizon 2020 program selects Precision NanoSystems’ NanoAssemblr platform to develop RNA medicines
 
Horizon 2020 program selects Precision NanoSystems’ NanoAssemblr platform to develop RNA medicinesPrecision NanoSystems NanoAssemblr platform has been selected for the controlled manufacture of nanomedicines as part of the multinational B-SMART (Brain-Specific, Modular and Active RNA Therapeutics) translational research project.
 
 
 Research projects provide better understanding on opportunities and risks of nanomaterials
 
Research projects provide better understanding on opportunities and risks of nanomaterialsIn the past six years, the National Research Programme "Opportunities and Risks of Nanomaterials" (NRP 64) intensively studied the development, use, behaviour and degradation of engineered nanomaterials, including their impact on humans and on the environment.
 
 
 Using nanodiamonds to see smaller
 
Using nanodiamonds to see smallerMany of the most fundamental, life governing biological processes take place at size and time scales that remain invisible with current imaging technologies. Understanding how the molecules that underlie these processes move, interact and change could pave the way for new treatments, cures and the development of novel drug therapies.
 
 
 Tiny light-emitting particles may provide unprecedented detail in biological imaging
 
Tiny light-emitting particles may provide unprecedented detail in biological imagingFor certain frequencies of short-wave infrared light, most biological tissues are nearly as transparent as glass. Now, researchers have made tiny particles that can be injected into the body, where they emit those penetrating frequencies.
 
 
 MIT engineers develop more sensitive approach to reveal ovarian tumors
 
MIT engineers develop more sensitive approach to reveal ovarian tumorsMost ovarian cancer is diagnosed at such late stages that patients' survival rates are poor. However, if the cancer is detected earlier, five-year survival rates can be greater than 90 percent.
 
 
 Microparticles show potential to deliver DNA-based vaccines and gene therapies in pill form
 
Microparticles show potential to deliver DNA-based vaccines and gene therapies in pill formA microscopic corn-and-shrimp cocktail could eventually make DNA-based vaccinations and cancer-treating gene therapies an easier pill to swallow, according to new research from the University of Nebraska-Lincoln.
 
 
 Clemson University researcher receives NIH grant to advance study into abdominal aortic aneurysms
 
Clemson University researcher receives NIH grant to advance study into abdominal aortic aneurysmsOne of the top ten killers for men older than 55 is the target of Clemson University research that could lead to a new life-saving therapy and a better way of telling whether surgery is necessary.
 
 
 Microscopic probes simplify process of measuring electrical signals in small animals
 
Microscopic probes simplify process of measuring electrical signals in small animalsMicroscopic probes developed at Rice University have simplified the process of measuring electrical activity in individual cells of small living animals. The technique allows a single animal like a worm to be tested again and again and could revolutionize data-gathering for disease characterization and drug interactions.
 
 
 Remote Magnetic Activation of Cytokines in Cancer Treatment
 
Remote Magnetic Activation of Cytokines in Cancer TreatmentCytokines are a group of small proteins or glycoproteins that regulate key intracellular communication within the body. While most of these small proteins are generated by the cells of the immune system, they can still play a role in many additional non-immune processes including cell differentiation and migration.
 
 
 KBI Biopharma Gains Commercial Benefit using Malvern Instruments
 
KBI Biopharma Gains Commercial Benefit using Malvern InstrumentsThe Particle Characterization Core Facility based at KBI Biopharma in Boulder, Colorado, is managed by Dr. Amber Fradkin. Headquartered in Durham, North Carolina, KBI is a biopharmaceutical contract development and manufacturing organization (CDMO) that focuses on expediting the development of biological therapeutics.